• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Best Read Articles on FDA News in 2021

News
Article

The FDA's warning about Xeljanz (tofacitinib) and other JAK inhiitors and the extension of its review of Janssen's CAR T therapy for multiple myeloma were among the best read articles about the agency in 2021.

FDA approves sNDAs for Vazalore

Application was submitted for both the 81 and 325 mg doses of the liquid-filled capsule formulation of aspirin.

Read more

FDA Rejects EUA for COVID-19 Respiratory Failure Therapy

The FDA didn’t have enough data to assess the risks and benefits of Zyesami.

Read more

FDA Extends Review of Janssen’s CAR T Therapy for Multiple Myeloma

The agency needs more time to review new information on the analytical method used.

Read more

FDA’s New Warning Includes Xeljanz, Other JAK Inhibitors

The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious cardiovascular events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.

Read more

FDA Pauses Clozapine REMS Program

New requirements resulted in long call wait times, which has led to patient access issues.

Read more

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.